C. Frank Bennett, Ph.D.

Senior Vice President, Research

Dr. Bennett is Senior Vice President of Research at Ionis Pharmaceuticals. He is responsible for preclinical antisense drug discovery and antisense technology research. Dr. Bennett is also the franchise leader for the Neurological Programs at Ionis. He is one of the founding members of the Company. Dr. Bennett has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry. Dr. Bennett has published more than 175 papers in the field of antisense research and development and has more than 150 issued U.S. patents.

Prior to joining Ionis, Dr. Bennett was Associate Senior Investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories, currently, GlaxoSmithKline.

Dr. Bennett received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. Dr. Bennett performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories. Dr. Bennett serves on the Advisory Board for the Experimental Therapeutics Centre in Singapore and the Scientific Committee for the American Society of Gene and Cell Therapy.